Eli Lilly is a global pharmaceutical company whose incretin franchise, led by Mounjaro and Zepbound, has become the dominant growth engine in diabetes and obesity care.
LLY
· Healthcare · Drug Manufacturers - General
· Market cap $1114.76B
QuantHub Original Research · Updated 2026-09-26
·
High QualityA-tier business, B-tier valuation with 2.1% upside to $1208 fair value.Fair Value
LLY is trading near fair value. No urgent action needed.
QuantHub Research: Investment Thesis
Investing Phase
Eli Lilly is a global pharmaceutical company whose incretin franchise, led by Mounjaro and Zepbound, has become the dominant growth engine in diabetes and obesity care. The business quality is high: TTM gross margin is 83.4%, TTM operating margin is 49.7%, TTM net margin is 33.5%, and ROE is 92.6%, while revenue grew 47.7% and earnings grew 25.3% in the most recent quarter on a year-over-year basis. The stock trades at $1183.72 against a blended fair value estimate of $1208.00, implying only 2.1% upside, with a P/S of 13.99, trailing P/E of 39.55, P/FCF of 52.68, and EV/EBITDA of 26.8. The valuation regime is characterized as fair relative to the company's five-year history, and analyst consensus is Strong Buy with a $1208 average target that matches the fair value estimate. The core tension is that Lilly's exceptional fundamentals are already reflected in the multiple, while product concentration, realized price declines of 13% in Q2 2026, and intense competition from Novo Nordisk in both injectable and oral obesity markets create meaningful execution risk. With the shares essentially at fair value, the risk-reward is balanced rather than compelling, and the investment case rests on continued incretin volume growth and pipeline conversion rather than multiple expansion.
Lilly is not cheap on absolute multiples: 13.99 times sales, 39.55 times trailing earnings, 52.68 times free cash flow, and 26.8 times EV/EBITDA. The market is pricing in continued hypergrowth from the incretin franchise, and the stock sits only 2.1% below the $1208 blended fair value estimate and the $1208 analyst consensus target. The valuation regime is classified as fair versus the company's own five-year history, meaning the premium multiple is consistent with how Lilly has traded during its recent growth phase rather than an anomaly. The gap between the Strong Buy consensus and the minimal upside to target suggests analysts see the shares as appropriately valued with limited near-term re-rating potential. Realized price declines of 13% in Q2 2026 and a 24,303 versus 147,500 weekly prescription gap for Foundayo against Novo Nordisk's oral Wegovy are the kinds of competitive and pricing data points that could cap multiple expansion even as volumes grow.
12–18 Month Outlook
In 18 months, Lilly will likely still be the dominant incretin player, but the growth narrative will be tested by whether Mounjaro and Zepbound can sustain volume growth against a 13% realized price decline and intensifying competition from Novo Nordisk. The oral obesity market is the key battleground: Foundayo's current 24,303 weekly prescriptions versus 147,500 for Novo Nordisk's oral Wegovy means Lilly must close a substantial gap to avoid ceding the oral segment. Revenue growth of 47.7% in the most recent quarter is unlikely to persist at that rate indefinitely given the law of large numbers and pricing pressure, and the stock's 52.68 times free cash flow multiple leaves little room for disappointment. With only 2.1% upside to the $1208 fair value estimate, the shares are fairly valued, and the next 18 months are more about defending and converting the pipeline than about multiple expansion. If retatrutide or Foundayo disappoints, the downside could be meaningful given the premium multiple.
Bull vs Bear
Bull Case
Revenue grew 47.7% year over year in the most recent quarter, and earnings grew 25.3% over the same period, demonstrating that the incretin franchise is still compounding at a pace few large-cap pharmaceutical companies can match.
TTM gross margin of 83.4%, TTM operating margin of 49.7%, and TTM net margin of 33.5% reflect exceptional pricing power and operating leverage, while ROE of 92.6% shows highly efficient use of shareholder capital.
Mounjaro and Zepbound represented 65% of first-half 2026 revenue, giving Lilly a concentrated but enormously profitable leadership position in the fastest-growing category in pharmaceuticals.
Analyst consensus is Strong Buy with a $1208 average target, and the blended fair value estimate of $1208 implies the shares are not overvalued relative to fundamental expectations.
The pipeline, including retatrutide and the oral obesity candidate Foundayo, provides optionality for additional revenue streams beyond the current injectable incretin portfolio.
Bear Case
Product concentration is extreme: Mounjaro and Zepbound accounted for 65% of first-half 2026 revenue, so any slowdown, safety issue, or competitive share loss in these two products would materially impair the entire company.
Global realized prices fell 13% in Q2 2026, and payer rebates, government access expansion, global price controls, and Inflation Reduction Act exposure for Jardiance, Trulicity, and Verzenio could pressure margins further.
Competitive intensity is high: Novo Nordisk's oral Wegovy recorded 147,500 weekly prescriptions versus 24,303 for Lilly's Foundayo, a material early gap in the oral obesity market.
The stock trades at 52.68 times free cash flow and 26.8 times EV/EBITDA with only 2.1% upside to the $1208 fair value estimate, leaving little margin of safety if growth decelerates.
Foundayo carries safety warnings including pancreatitis, severe gastrointestinal reactions, acute kidney injury, hypoglycemia, and gallbladder disease, and retatrutide remains investigational with no assurance of future approval or commercial success.
Leadership & Competitive Position
David A. Ricks
Tenure9 yrs
Beats guidance75% of qtrs
Capital allocationGood
David A. Ricks has served as CEO of Eli Lilly and Company and has overseen a period in which the company became the largest healthcare company by market capitalization, driven by the success of its incretin franchise. The company's TTM return on equity of 92.6% and TTM operating margin of 49.7% indicate strong execution under current leadership. Capital allocation has prioritized research and development and manufacturing capacity expansion to meet incretin demand, though the company carries significant product concentration risk that is a strategic rather than purely operational challenge.
Competitive Moat
stable
intangible assetscost advantage
Lilly's Mounjaro and Zepbound represented 65% of first-half 2026 revenue, indicating a dominant position in the incretin category. However, in the oral obesity market, Foundayo recorded 24,303 weekly prescriptions versus 147,500 for Novo Nordisk's oral Wegovy, showing Lilly is currently trailing in that specific segment.
Competitors: Novo Nordisk (NVO), Pfizer (PFE), Merck (MRK), AstraZeneca (AZN)
Disruption: Medium. The incretin market is highly competitive with Novo Nordisk as a formidable rival, and oral obesity treatments represent a potential format shift where Lilly currently trails. Pricing pressure from government programs and payer rebates adds another layer of disruption risk.
QuantHub Research
Valuation
Multiple
Current
Median 3yr
Median 5yr
Min 5yr
Max 5yr
P/E
39.55x
65.65x
55.68x
46.58x
99.99x
P/S
13.99x
15.36x
14.81x
9.3x
15.44x
P/FCF
52.68x
75.56x
75.56x
48.89x
107.56x
P/S 13.99x vs 5yr range 9.3-15.44x (P25=9.3x, median=14.81x, P75=15.36x)
Price Outlook (5-Year)
Bear
$966
-4.0%/yr
Base
$1208
0.4%/yr
fair value
Bull
$1450
4.1%/yr
Bear/Base/Bull anchored to QuantHub fair value estimate. Base = headline fair value; Bear −20%; Bull +20%.
Mounjaro and Zepbound represented 65% of first-half 2026 revenue, increasing Lilly's dependence on a narrow set of incretin products for revenue growth and earnings.
Pricing and reimbursement pressure
high
Global realized prices fell 13% in Q2 2026. Payer rebates, government access expansion, global price controls, and Inflation Reduction Act pricing exposure for products including Jardiance, Trulicity, and Verzenio may further pressure realized prices and margins.
Manufacturing and supply execution
medium
Demand for incretin medicines remains unusually high, making capacity expansion, labor availability, third-party performance, quality control, supply-chain continuity, cybersecurity, and regulatory compliance critical to revenue conversion and market-share retention.
Competitive intensity
high
Novo Nordisk is Lilly's principal incretin competitor. In the oral obesity market, Foundayo recorded 24,303 weekly prescriptions versus 147,500 for Novo Nordisk's oral Wegovy, indicating a material early prescription gap.
Clinical and safety risk
medium
Foundayo carries safety warnings including pancreatitis, severe gastrointestinal reactions, acute kidney injury, hypoglycemia, and gallbladder disease. Retatrutide remains investigational, so future efficacy, safety, regulatory, and commercialization outcomes are not assured.
Valuation and multiple compression risk
medium
The stock trades at 52.68 times free cash flow and 26.8 times EV/EBITDA with only 2.1% upside to the $1208 fair value estimate. Any growth deceleration or margin pressure could trigger multiple compression given the premium valuation.
Growth Engines
Incretin injectable franchisescaling
Mounjaro and Zepbound address diabetes and obesity markets with enormous global demand, representing 65% of first-half 2026 revenue and growing rapidly.
Oral obesity treatment Foundayoearly
The oral obesity market is large and growing, but Foundayo's 24,303 weekly prescriptions trail Novo Nordisk's oral Wegovy at 147,500, indicating early-stage competitive positioning.
Oncology portfoliomature
Verzenio, Retevmo, Cyramza, Erbitux, and Alimta provide diversified oncology revenue, though Verzenio faces Inflation Reduction Act pricing exposure.
Retatrutide pipelineearly
Retatrutide remains investigational, so its efficacy, safety, regulatory, and commercialization outcomes are not assured, but it represents potential future growth in metabolic disease.
Recent news flow around Eli Lilly as of late September 2026, with the company continuing to trade near its $1208 fair value estimate and analyst consensus target.
This is AI-powered fundamental analysis built from scratch — not aggregated analyst ratings. Get this research for your entire portfolio plus daily briefings, research signals, and options income.
QuantHub research is focused on quality businesses with durable competitive advantages — companies we'd want to own for 3–5 years or more. We are not short-term traders. Every analysis is built around a single question: is this a great business available at a reasonable price for a long-term investor?
We start where most analysts finish: the fundamentals. For every company, our AI ingests years of financial statements — revenue, margins, free cash flow, and how the business has been valued by the market across multiple cycles. But numbers alone don't tell you whether a business is worth owning.
The harder work is qualitative. We assess the competitive moat: is it widening or eroding? We read the leadership track record — how capital has been allocated, whether management has earned trust through consistent execution. We look at what the market is afraid of, and whether that fear is priced in fairly or irrationally.
Valuation is always relative. A stock is cheap or expensive compared to its own history. We build scenario matrices anchored to 5-year historical multiples, then ask: what has to go right for the upside case, and what's the floor if it doesn't?
Finally, we write an 18-month forward outlook — not a price target, but a mental model of where this business will be and what the narrative will look like. Every note is dated and versioned. When material facts change, we update the thesis.
Frequently Asked Questions
Is LLY undervalued?
LLY is currently fairly valued at $1,183.72 vs. our fair value estimate of $1,208.00 (+2% upside).
What is LLY's fair value?
QuantHub Research estimates LLY's fair value at $1,208.00 based on our proprietary valuation model incorporating historical P/S, P/E, and P/FCF multiples over a 5-year range.
What are the key risks for LLY?
Product concentration risk: Mounjaro and Zepbound represented 65% of first-half 2026 revenue, increasing Lilly's dependence on a narrow set of incretin products for revenue growth and earnings. Pricing and reimbursement pressure: Global realized prices fell 13% in Q2 2026. Payer rebates, government access expansion, global price controls, and Inflation Reduction Act pricing exposure for products including Jardiance, Trulicity, and Verzenio may further pressure realized prices and margins. Manufacturing and supply execution: Demand for incretin medicines remains unusually high, making capacity expansion, labor availability, third-party performance, quality control, supply-chain continuity, cybersecurity, and regulatory compliance critical to revenue conversion and market-share retention.
What is the bull case for LLY?
Revenue grew 47.7% year over year in the most recent quarter, and earnings grew 25.3% over the same period, demonstrating that the incretin franchise is still compounding at a pace few large-cap pharmaceutical companies can match. TTM gross margin of 83.4%, TTM operating margin of 49.7%, and TTM net margin of 33.5% reflect exceptional pricing power and operating leverage, while ROE of 92.6% shows highly efficient use of shareholder capital. Mounjaro and Zepbound represented 65% of first-half 202
How confident is QuantHub in LLY?
QuantHub has moderate conviction in LLY. Research last updated 2026-09-26.